MktsMarkets

Nuvectis Pharma, Inc.
NASDAQ: NVCTKey statistics
NVCT News
Stories mentioning NVCT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 4,106 | 5,086 | 5,774 | 3,613 | 3,680 | 4,496 | 2,819 | 2,943 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (6,260) | (7,617) | (7,794) | (6,595) | (5,568) | (6,449) | (4,359) | (4,643) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (6,050) | (7,314) | (7,462) | (6,334) | (5,332) | (6,248) | (4,153) | (4,428) |
| Earnings Per Share (Basic) | (0.26) | (0.34) | (0.44) | (0.30) | (0.27) | (0.37) | (0.24) | (0.26) |
| Earnings Per Share (Diluted) | (0.26) | (0.34) | (0.44) | (0.30) | (0.27) | (0.37) | (0.24) | (0.26) |
| Weighted Average Shares Outstanding (Basic) | 23,414 | 21,813 | 22,719 | 21,366 | 19,938 | 17,113 | 17,231 | 16,901 |
| Weighted Average Shares Outstanding (Diluted) | 23,414 | 21,813 | 22,719 | 21,366 | 19,938 | 17,113 | 17,231 | 16,901 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NVCT
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a stock listed on the Nasdaq Stock Market under the ticker symbol NVCT. It last traded at $20.12 (Oct 20, 2026, 12:29 PM ET), up 6.2% on the day. That gives Nuvectis Pharma a market capitalisation of $618.3M.
Over the past 52 weeks NVCT has traded between $5.55 and $29.27.
For the quarter ended Mar 31, 2026 it reported a net loss of $6.1M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$6.1M |
| Dec 31, 2025 | — | -$7.3M |
| Sep 30, 2025 | — | -$7.5M |
| Jun 30, 2025 | — | -$6.3M |
From Nuvectis Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…